TC
NVO

Tacita Capital’s Novo Nordisk NVO Stock Holding History

Tacita Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-169
Closed -$6.21K – 234
2026
Q1 		$6.21K Hold
169
– – ﹤0.01% 229
2025
Q4 		$8.6K Hold
169
– – 0.01% 201
2025
Q3 		$9.38K Hold
169
– – 0.01% 199
2025
Q2 		$11.7K Hold
169
– – 0.01% 191
2025
Q1 		$11.7K Hold
169
– – 0.01% 183
2024
Q4 		$14.5K Hold
169
– – 0.01% 178
2024
Q3 		$20.1K Hold
169
– – 0.01% 167
2024
Q2 		$24.1K Hold
169
– – 0.02% 168
2024
Q1 		$21.7K Sell
169
-67
-28% -$7.98K 0.02% 173
2023
Q4 		$24.4K Buy
+236
New +$23.3K 0.02% 172

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Tacita Capital's NVO Position: Q2 2026 in Review

Tacita Capital sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 169 shares — an estimated $6.21K sold.

Tacita Capital first reported a position in NVO in Q4 2023 and held it in 10 quarters. The position peaked at $24.4K in Q4 2023. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Tacita Capital reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Tacita Capital sold 169 Novo Nordisk shares in Q2 2026, an estimated $6.21K.
  • Tacita Capital first reported a position in Novo Nordisk in Q4 2023 and held it in 10 quarters.
  • Tacita Capital's Novo Nordisk position peaked at $24.4K in Q4 2023.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Tacita Capital's 13F filing for Q2 2026, filed 10 Aug 2026.